Log in

Cancer: AstraZeneca sells the rights of Zoladex in North America

The British pharmaceutical company AstraZeneca announced Friday the sale of marketing rights in the United States and Canada, Zoladex, a treatment against cancers of the prostate and breast, to 250 million.

The group explained that the sales rights of this treatment, also used for benign gynecological disorders, would be sold to the US pharmaceutical company TerSera Therapeutics.

The British group said its incentive to future sales of Zoladex could bring him up to 70 million dollars. He will receive moreover equivalent to fifteen percent of revenue from future sales of the treatment in these two countries.

In a separate statement, AstraZeneca announced that the US Food and Drug Administration (FDA) approved the use of Tagrisso, a drug used against the lung cancer non-small cell.

Oncology business is a strategic priority for AstraZeneca, which has strengthened in this area in recent years by continuing its work in R & D, by forging partnerships with other companies and conducting a few targeted acquisitions.

a3p-100pxhaut logo


Commit to share
Transmit and progress together
Promoting innovation

The A3P Association is a major player in the pharmaceutical and biotechnology industry.
Created in 1986, it contributes to the good development of the production of medicines and clean and sterile equipment, it runs a network of professionals 21 000, manufacturers and suppliers, as part of International Congress and technical days.

It now has over 1700 members who share their technical experience, scientific and regulatory.

More info on video (Versiongb - drapeauitalie )

  group    administrators A3P
& Project Managers

letter   newsletter A3P